Insider buying last 90 days
No open-market insider purchases were filed for SYK in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every SYK insider filing, plotted on the chart in Gekko.Open SYK in Gekko
NYSE: SYK
Stryker (SYK) Stock Analysis & Forecast
$275.12−5.01 (−1.8%)
Close on Sep 18, 2026. Page updated Sep 19, 9:15 pm ET.
Gekko Brief
AI summaryStryker (SYK) closes at $275.12, down 1.8%, and sits below both its 50-day average of $320.40 and 200-day average of $334.39, with the 50-day also below the 200-day. The GekkoIndex reads 71.3, placing the stock in the Buying zone, while price stands 17.1% below Gekko Fair Value of $331.69.
This week's coverage centers on manufacturing problems in the Peripheral Vascular business and unexpected seasonality in Joint Replacement, which prompted Canaccord Genuity to lower its price target to $385.00 from $400.00 while maintaining a Buy rating. The CFO's disclosure that a previously-thought resolved manufacturing issue persists preceded a share drop of $26.70, or 8.8%, on 8 September. Separately, Stryker expanded its Foot & Ankle portfolio with Prophecy Surgical Planning for the Incompass Total Ankle System and Hoffmann LRF smartHEX, showcased at the AOFAS 2026 Annual Meeting. Legal investigations by Bronstein, Gewirtz & Grossman and Block & Leviton into potential securities claims tied to the stock's declines were also disclosed.
The next earnings report is scheduled for 29 October 2026, after close, 39 days away and outside a typical 20-trading-day hold; the prior quarter saw an EPS beat of $3.69 versus $3.46 estimated, with a -7.5% reaction. Seasonality over the next 20 trading days has averaged -2.8% across 5 years, with 0 of those years positive. Analyst consensus among 18 firms stands at 16 buy and 2 hold ratings, with a consensus target of $374.88. No insider, Congress, or unusual options activity appears in the current windows.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $275.12200-day averageGekko Fair Value $331.69
Key stats
- Market cap
- $105.5B
- P/E ratio
- 29.5
- Forward P/E
- 17
- EPS, TTM
- $9.50
- Revenue, TTM
- $25.84B
- Profit margin
- 14.4%
- Dividend yield
- 1.22%
- Beta
- 0.77
- Volume
- 4.61M avg 2.97M
- 1-year return
- −27.0%
- Typical daily move
- ±3.8%
- Typical 20-day move
- ±4.3%
- 50-day average
- $320.40
- 200-day average
- $334.39
- Next earnings
- Oct 29 after close
- Shares outstanding
- 383.6M
Stryker swing-trade checklist
Stryker scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $275.12 is below the 50-day ($320.40) and 200-day ($334.39) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
71.3, Buying
Reading 71.3 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
17.1% below
Price is 17.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 39 days
Next report Oct 29, 2026, 39 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−2.8% on average
From this point in the calendar, the next 20 trading days averaged −2.8% over 5 years, rising in 0 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Stryker stock chart and price history
Stryker closed at $275.12 on Sep 18, 2026, −27.0% over the past year, inside a 52-week range of $267.00 to $392.55.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −19.1%
- 3 months
- −10.6%
- 6 months
- −19.0%
- 1 year
- −27.0%
The full SYK chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SYK in Gekko
Follow Stryker through every session
Put SYK on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track SYK in GekkoFree for 7 days. No credit card required.
About Stryker
Stryker makes medical technology used in surgery and patient care, with much of its recognition tied to joint replacement implants for hips and knees as well as spinal hardware used in treating injuries, deformities and degenerative conditions of the spine.
The company organizes its work into two broad areas. One centers on orthopaedic implants and trauma and extremities repair, along with spinal systems covering cervical, thoracolumbar and interbody needs. The other spans surgical equipment, navigation systems, endoscopy and communication tools, patient handling and emergency care devices, and disposable items used in critical care, plus reprocessed and remanufactured devices. Within this second area, Stryker also supplies neurotechnology products, including tools for endovascular procedures, brain and skull-base surgery, synthetic bone grafts, vertebral augmentation, stroke treatment devices, craniomaxillofacial implants, and dural substitutes and sealants. Its customers are doctors, hospitals and other healthcare providers, reached through its own subsidiaries, regional offices, and outside dealers and distributors across roughly 75 countries.
Stryker was founded in 1941 and is headquartered in Kalamazoo, Michigan. Its shares are listed on the NYSE under the ticker SYK.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- stryker.com
Stryker GekkoIndex: the smart money zone
Stryker’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 71.3, in the Buying zone, down 4.1 points over five sessions.
71.3Buying
Down 4.1 points over five sessions.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 30 | +1.5% | +3.7% | ||
| Accumulation | 232 | +0.2% | +1.9% | ||
| Neutral | 371 | −0.3% | −1.4% | ||
| Distribution | 28 | +0.3% | +0.4% | ||
| Selling | 1 | Too few readings yet | |||
Average SYK share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.2% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the SYK price, zone by zone.Track SYK in Gekko
Is Stryker stock overvalued? Gekko Fair Value
Stryker trades 17.1% below Gekko Fair Value of $331.69, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Stryker shares are worth, recalculated every trading day.
$331.69
Gekko Fair Value, Sep 19, 2026
17.1% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open SYK in Gekko
Stryker insider and Congress trading
No open-market insider purchases were filed for Stryker, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in SYK were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for SYK, plotted on the chart in Gekko.Open SYK in Gekko
Buybacks
Stryker has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2026
- $139.0M
- As a share of market cap
- 0.13%
- Trailing four quarters
- $187.0M
From company filings.
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold SYK.
1added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Stryker earnings: next date and track record
Stryker reports on Oct 29, 2026, after the close (39 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Oct 29, 2026
Expected after the close, 39 days away
- EPS estimate
- $3.62
- Revenue estimate
- $6.66B
7 of 8reports beat the EPS estimate
±4%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 30, 2026 AI summary
- What they said
- Stryker's Q2 earnings call highlighted a strong operational recovery following a cybersecurity incident, with consolidated organic sales growth of 9% and adjusted EPS up 17.9% year-over-year. Management emphasized broad-based strength across MedSurg & Neurotechnology and international markets, record Mako installations and positive early feedback on Mako RPS, while noting an acute supply disruption in the peripheral vascular (Inari) business that created elevated backorders expected to be manageable by end of Q3. Management reiterated confidence in the capital environment, an elevated backlog, and the long-term opportunity in international markets and new product launches (e.g., Triathlon Gold, Sonopet, SmartCare). They also discussed margin dynamics: continued commitment to operational improvement (150 bps over 3 years), tariff refunds that benefited Q2 results, offset by cyber-related remediation costs, lost absorption, and commodity pressures. Capital allocation priorities remain M&A first, with opportunistic share repurchases (board-approved ~$1B available) contemplated. Management maintained (and narrowed) guidance for the year, expressed confidence in production ramp to satisfy backlog and capital orders, and expects to provide an update at Q3.
- Guidance
- Updated organic sales guidance narrowed to an approximate range of 8.3% to 9.3% growth for the full year (management noted they raised the lower end from ~8% to 8.3%). Management expects backorders from the Inari supply disruption to be manageable by end of Q3. They reiterated EPS guidance range (not numerically specified on the call) but noted continued commitment to margin improvement (150 bps over three years). Potential timing: IVL (AVS product) could receive approval and begin sales before year-end (possible, not guaranteed).
- Risks flagged
- Cybersecurity incident impacts (production outages, remediation costs, lost absorption); acute supply disruption at a single Inari plant causing backorders and lost sales in peripheral vascular; raw material / commodity pressures; uncertainty in procedure volumes across geographies and potential reimbursement headwinds (Medicare proposed changes); integration risks from acquisitions and salesforce transitions.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | $3.69 est $3.46 | $6.59B est $6.58B | −7.5% |
| Apr 30, 2026 | $2.60 est $2.98 | $6.02B est $6.34B | −6.5% |
| Jan 29, 2026 | $4.47 est $4.40 | $7.17B est $7.12B | +3.3% |
| Oct 30, 2025 | $3.19 est $3.13 | $6.06B est $6.04B | −3.6% |
| Jul 31, 2025 | $3.13 est $3.07 | $6.02B est $5.94B | −5.6% |
| May 1, 2025 | $2.84 est $2.71 | $5.87B est $5.69B | +1.1% |
| Jan 28, 2025 | $4.01 est $3.87 | $6.44B est $6.36B | −2.2% |
| Oct 29, 2024 | $2.87 est $2.77 | $5.49B est $5.37B | +2.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Stryker stock forecast and analyst price targets
Analysts’ average 12-month price target for Stryker is $374.88, +36.3% from the last close, from 18 firms rating the stock in the last 90 days.
$374.88consensus 12-month target, +36.3% from the last close
Now $275.12Avg $374.88
Low $317High $420
Each firm’s latest rating in the last 90 days: 18 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 18 | Canaccord Genuity | $385 | +39.9% |
| Sep 16 | RBC Capital | $420 | +52.7% |
| Sep 16 | Wells Fargo | $348 | +26.5% |
| Sep 15 | Bank of America Securities | $380 | +38.1% |
| Sep 10 | Citi | $360 | +30.9% |
+3.7%average 20-day move after past Buying readings
−2.8%average move over the next 20 trading days in the last 5 years
±3.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Stryker seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Stryker averaged −2.8% across the last 5 years, rising in 0 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.1% | 1 of 5 |
| Next 10 trading days | −4.0% | 0 of 5 |
| Next 15 trading days | −4.2% | 0 of 5 |
| Next 20 trading days | −2.8% | 0 of 5 |
| Next 30 trading days | −1.8% | 3 of 5 |
For scale, SYK’s typical 20-trading-day move in either direction is about 4.3%.
Stryker market cap and key statistics
Stryker’s market cap is $105.5B, with a P/E ratio of 29.5 and revenue of $25.84B over the last twelve months.
Valuation
- Market cap
- $105.5B
- P/E ratio
- 29.5
- Forward P/E
- 17
- EPS, TTM
- $9.50
- Gekko Fair Value
- $331.69
Trading
- Volume
- 4.61M
- Avg volume, 20 days
- 2.97M
- 52-week high
- $392.55
- 52-week low
- $267.00
- Shares outstanding
- 383.6M
Financials
- Revenue, TTM
- $25.84B
- Profit margin
- 14.4%
- Return on equity
- 16.5%
- Quarterly earnings growth, YoY
- +44.1%
Risk and income
- Beta
- 0.77
- Typical daily move
- ±3.8%
- Typical 20-day move
- ±4.3%
- Dividend yield
- 1.22%
Stryker stock news this week
Coverage of Stryker this week reads negative: 6 positive, 0 neutral and 7 negative headlines.
- Stryker Corporation (SYK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationACCESS Newswire, Sep 18
- Stryker (NYSE:SYK) Given New $385.00 Price Target at Canaccord Genuity GroupMarketBeat, Sep 18
- SYK Investors: Contact Block & Leviton Regarding Its Ongoing Investigation of Stryker CorporationNewsfile Corp, Sep 18
- Nykredit A S Purchases Shares of 282,407 Stryker Corporation $SYKMarketBeat, Sep 18
- Canaccord cuts Stryker stock price target on manufacturing woesInvesting.com, Sep 17
- Canaccord cuts Stryker stock price target on manufacturing woes By Investing.comInvesting.com Canada, Sep 17
Stryker peers
Stryker’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 17.1% above |
| ABTAbbott Laboratories | Accumulation | 15.5% below |
| DHRDanaher | Neutral | 1.1% above |
| ISRGIntuitive Surgical | Neutral | 12.3% above |
| MDTMedtronic | Neutral | 24.7% below |
| BSXBoston Scientific | Accumulation | 35.9% below |
A peer links to its own page where one exists.
Stryker stock FAQ
What is Stryker’s market cap?
Stryker’s market cap is $105.5B at the Sep 18, 2026 close of $275.12, with 383.6M shares outstanding. The shares trade on a P/E ratio of 29.5.
What is the Stryker stock forecast?
The consensus analyst 12-month price target for Stryker is $374.88, +36.3% from the last close. Of the 18 firms that rated the stock in the last 90 days, 16 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Stryker stock overvalued or undervalued?
On Gekko’s estimate Stryker is undervalued: the Sep 18, 2026 close of $275.12 is 17.1% below Gekko Fair Value of $331.69. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Stryker report earnings next?
Stryker is expected to report on Oct 29, 2026, after the market closes (39 days away). Analysts expect earnings of $3.62 per share on revenue of $6.66B. Stryker beat the earnings estimate in 7 of its last 8 reports, moving 4% on average across the report.
What is Stryker’s 52-week high and low?
Stryker’s 52-week high is $392.55 and its 52-week low is $267.00; it closed at $275.12 on Sep 18, 2026, −27.0% over the past year.
Is Stryker stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Stryker the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.